Chugai Pharmaceutical Co Ltd

4519.T · Health Technology · Pharmaceuticals: Major · JP

7,555 employees · chugai-pharm.co.jp

About

Chugai Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1925. It is headquartered in Tokyo and employs over 7,500 employees worldwide. Chugai is one of the largest pharmaceutical companies in Japan and has become a global company with a strong research and development department in recent decades. The business model of Chugai is based on the development and production of drugs for various medical conditions, with a focus on cancer therapy. However, Chugai also has drugs for other medical conditions in its portfolio, such as rheumatism, asthma, and diabetes. The company specializes in research and development of biotechnological therapeutics and has focused on the study of biological agents. Chugai's goal is to improve people's lives and enhance patient care. Chugai is divided into several business units, each focusing on different areas of therapy. One of these areas is oncology. Chugai has a strong range of oncology products, for which it is a market leader in Japan. These include Avastin, an anti-angiogenesis drug for the treatment of colorectal, breast, lung, and kidney cancer, as well as Herceptin for the treatment of breast and gastric cancer, and Tarceva for treating bronchial carcinomas. Another important business area of Chugai is rheumatology. Here, Chugai offers various products such as Actemra, a monoclonal antibody against the interleukin-6 receptor used in rheumatoid arthritis, as well as Rituxan, an antibody against the CD20 antigen used in the treatment of lymphomas. In addition to drug development and manufacturing, Chugai also conducts research and development in the field of diagnostics. This is an important complement to the company's therapeutic portfolio. Chugai develops diagnostics to improve disease diagnosis. Another important area of Chugai is the outsourcing of research and development services. Chugai collaborates with many international pharmaceutical companies, offering its expertise and infrastructure in the development of new drugs. Chugai Pharmaceuticals is a significant player in global healthcare and aims to establish itself as a leading company in biological and cellular preparation research. The company invests significant resources in the exploration of new technologies to ensure sustainable therapy options. Chugai Pharmaceuticals has built a strong presence in the global market in recent years and will continue to play an important role in the future.

Annual results

Reported figures, JPY · revenue up 7.5% in 2025

YearRevenueNet incomeNet marginFree cash flow
20251.3T434B34.5%—
20241.2T387B33.1%—
20231.1T325B29.3%—
20221.3T374B29.7%—
20211000B303B30.3%—

Dividends per share

2026 141.00 JPY2025 132.00 JPY2024 81.00 JPY2023 80.00 JPY2022 84.00 JPY

4519.T in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Chugai Pharmaceutical Co Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Chugai Pharmaceutical Co Ltd (4519.T) — company profile and financials · MarketPulse